Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cladribine - Johnson and Johnson/Merck Serono

Next Previous
Drug Profile

Cladribine - Johnson and Johnson/Merck Serono

Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Mavenclad; Movectro; Mylinax; PRMavenclad; RWJ-26251

Latest Information Update: 02 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scripps Clinic
  • Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
  • Class Antineoplastics; Antipsoriatics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis; Leukaemia; Lymphoma; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
  • Phase III Myasthenia gravis
  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 24 Nov 2025 Cladribine - Johnson and Johnson/Merck Serono receives Fast Track designation for Myasthenia gravis [PO] in USA
  • 25 Jun 2024 Phase-III clinical trials in Myasthenia gravis in South Korea, USA (PO) (NCT06463587)
  • 25 Jun 2024 Phase-III clinical trials in Myasthenia gravis in Japan (PO) (NCT06463587)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top